Aachen, Germany, 30 September 2024 <\/strong>\u2013 Gr\u00fcnenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Gr\u00fcnenthal.<\/p>\n

Jan Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Gr\u00fcnenthal in 2017, he has been key in driving the company’s transformational journey. Under his leadership, Gr\u00fcnenthal successfully built a state-of-the-art R&D organisation, redefined its R&D strategy, and built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Before assuming the role of CSO, he served as Head of Strategy and Portfolio, working at the interface between Strategy, R&D, and Commercial. His role was instrumental in several successful M&A projects and Gr\u00fcnenthal\u2019s entry into the U.S. market. Before joining Gr\u00fcnenthal, he held positions with increasing responsibilities at Takeda, McKinsey & Company, and Novartis. Jan Adams started his career as a resident in cardiology. He is a Medical Doctor by training, married, and has two children.<\/p>\n

Jan Adams succeeds Janneke van der Kamp, who will leave Gr\u00fcnenthal to pursue an opportunity outside the company. We are grateful to Janneke for all she has done for Gr\u00fcnenthal and our people and wish her all the very best in her future endeavours.<\/p>\n

About Gr\u00fcnenthal<\/strong><\/p>\n

Gr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better \u2013 and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.<\/p>\n

Gr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Gr\u00fcnenthal employed around 4,400 people and achieved revenues of \u20ac1.8 billion.<\/p>\n

More information: https:\/\/www.grunenthal.com<\/a><\/p>\n

Follow us on:<\/p>\n

LinkedIn: Grunenthal Group<\/a><\/p>\n

Instagram: grunenthal<\/a><\/p>\n

For further information, please contact:<\/strong><\/p>\n<\/p><\/div>\n